Skip to main content
. 2020 Feb 21;64(3):e02177-19. doi: 10.1128/AAC.02177-19

TABLE 1.

Antimicrobial susceptibility of Enterobacterales, P. aeruginosa and resistant subsets collected in 2014–2018 from patients hospitalized with pneumonia and VAP

Antimicrobial agent PHP
VAP
MIC (mg/liter)
N CLSI (%)a
MIC (mg/liter)
N CLSI (%)a
50% 90% S R 50% 90% S R
Enterobacterales 4,790 814
    Meropenem-vaborbactam 0.03 0.06 >99.9 <0.1 0.03 0.06 100.0 0.0
    Meropenem 0.03 0.06 97.2 2.3 0.03 0.06 98.3 1.5
    Imipenem 0.25 1 92.8 3.6 0.25 1 94.3 2.2
    Cefepime ≤0.5 8 87.8b 9.2 ≤0.5 2 92.4 5.5
    Ceftazidime 0.25 32 82.8 15.6 0.25 32 85.3 13.4
    Ceftriaxone 0.12 >8 77.7 20.6 0.12 >8 80.6 17.2
    Piperacillin-tazobactam 2 64 87.3 7.1 2 64 87.0 7.5
    Aztreonam ≤0.12 >16 82.3 16.4 ≤0.12 >16 84.0 14.6
    Amikacin 2 4 98.7 0.3 2 4 99.1 0.1
    Gentamicin ≤1 2 91.3 7.5 ≤1 ≤1 95.3 3.6
    Tigecyclinec 0.25 1 96.6 0.3 0.25 1 97.1 0.2
    Levofloxacin ≤0.12 >4 80.7 16.8 ≤0.12 >4 84.3 12.8
    Colistind ≤0.5 >8 76.1 23.9 ≤0.5 >8 77.8 22.2
CREe 131 13
    Meropenem-vaborbactam 0.03 0.5 98.5 0.8 0.06 1 100.0 0.0
    Meropenem 16 >32 3.8 85.5 4 32 0.0 92.3
    Imipenem >8 >8 0.0 98.5 8 >8 0.0 84.6
    Cefepime >16 >16 8.4c 77.9 16 >16 30.8 53.8
    Ceftazidime >32 >32 4.6 93.1 >32 >32 15.4 76.9
    Ceftriaxone >8 >8 2.3 96.9 >8 >8 0.0 92.3
    Piperacillin-tazobactam >64 >64 3.8 89.3 >64 >64 7.7 61.5
    Aztreonam >16 >16 1.5 96.9 >16 >16 7.7 84.6
    Amikacin 8 32 73.3 6.1 2 32 84.6 7.7
    Gentamicin 4 >8 52.7 26.7 ≤1 >8 76.9 15.4
    Tigecyclinec 0.5 2 96.9 1.5 0.5 1 100.0 0.0
    Levofloxacin >4 >4 16.8 79.4 0.5 >4 53.8 38.5
    Colistind ≤0.5 >8 76.9 23.1 ≤0.5 >8 84.6 15.4
Pseudomonas aeruginosa 3,193 545
    Meropenem-vaborbactamd 0.5 16 89.5 10.5 0.5 16 88.8 11.2
    Meropenem 0.5 16 76.4 16.9 0.5 16 73.8 10.3
    Imipenem 1 >8 74.5 21.4 1 >8 77.2 22.8
    Cefepime 4 16 82.4 6.1 4 16 82.5 5.1
    Ceftazidime 2 32 81.7 13.2 2 32 82.4 12.7
    Piperacillin-tazobactam 4 >64 77.5 11.7 8 >64 74.3 11.9
    Aztreonam 8 >16 66.5 21.9 8 >16 63.7 23.5
    Amikacin 4 16 94.2 3.3 4 8 96.9 1.3
    Gentamicin 2 >8 82.5 10.3 2 8 85.0 9.0
    Levofloxacin 1 >4 62.0 26.7 0.5 >4 67.7 23.9
    Colistin 1 2 99.7 0.3 1 2 99.8 0.2
MDRf P. aeruginosa 697 124
    Meropenem-vaborbactamd 8 32 59.0 41.0 8 32 59.7 40.3
    Meropenem 8 32 22.1 63.1 8 32 21.0 38.7
    Imipenem 8 >8 22.8 69.6 8 >8 23.4 70.2
    Cefepime 16 >16 32.9 24.7 16 >16 34.7 20.2
    Ceftazidime 16 >32 35.3 48.5 16 >32 46.8 41.9
    Piperacillin-tazobactam 64 >64 23.0 43.6 64 >64 19.4 41.1
    Aztreonam >16 >16 16.8 66.7 >16 >16 15.3 67.7
    Amikacin 8 >32 80.8 12.1 8 16 90.3 3.2
    Gentamicin 8 >16 44.9 35.7 8 16 49.2 33.1
    Levofloxacin >4 >4 9.2 74.5 >4 >4 14.5 69.4
    Colistin 0.5 2 99.1 0.9 1 2 100.0 0.0
XDRg P. aeruginosa 440 70
    Meropenem-vaborbactamd 16 32 48.6 51.4 16 32 47.1 52.9
    Meropenem 16 32 10.0 76.6 16 32 10.0 72.9
    Imipenem >8 >8 13.2 79.5 8 >8 15.7 77.1
    Cefepime 16 >16 18.2 34.1 16 >16 20.0 24.3
    Ceftazidime 32 >32 23.9 58.4 16 >32 44.3 44.3
    Piperacillin-tazobactam >64 >64 8.9 53.2 64 >64 2.9 48.6
    Aztreonam >16 >16 9.5 77.3 >16 >16 10.0 78.6
    Amikacin 8 >32 76.8 23.2 8 32 87.1 5.7
    Gentamicin 8 >16 37.0 41.8 8 >16 40.0 40.0
    Levofloxacin >4 >4 2.5 83.6 >4 >4 1.4 81.4
    Colistin 0.5 1 99.1 0.9 1 2 100.0 0.0
a

Criteria as published by CLSI (38).

b

Intermediate interpreted as susceptible-dose dependent.

c

FDA breakpoints (39).

d Criteria as published by EUCAST (37).

e

CRE, carbapenem-resistant Enterobacterales.

f

MDR, multidrug resistant.

g

XDR, extensively drug resistant.